Safety and Tolerability of Tumor Necrosis Factor-α Inhibitors in Psoriasis: A Narrative Review

Effects of Biologic Agents and Other Disease-Modifying Antirheumatic Drugs on Cardiovascular Outcomes in Psoriasis and Psoriatic Arthritis: A Systematic Review

(2013) April W. Armstrong et al.   CURRENT PHARMACEUTICAL DESIGN

Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States

(2013) April W. Armstrong et al.   JAMA Dermatology

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

(2012) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of Serious Adverse Events Associated With Biologic and Nonbiologic Psoriasis Systemic Therapy

(2012) Gregorio Carretero   ARCHIVES OF DERMATOLOGY

Management of inflammatory bowel disease in pregnancy

(2012) Séverine Vermeire et al.   Journal of Crohns & Colitis

Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy

(2012) Elizabeth A. Brezinski et al.   PLoS One

Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150 000 pregnant women and expectant fathers

(2012) KK Viktil et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis

(2011) Craig Leonardi et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

TNF-α and the Development of the Neonatal Immune System: Implications for Inhibitor Use in Pregnancy

(2011) Razvan Arsenescu et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Methotrexate and misoprostol teratogenicity: Further expansion of the clinical manifestations

(2011) Chahira Kozma et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Rheumatoid Arthritis and Pregnancy

(2011) Ashima Makol et al.   DRUGS

Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy

(2011) Fabian Schnitzler et al.   INFLAMMATORY BOWEL DISEASES

Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases

(2011) Carlos G. Grijalva et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Comparing the lifetime risks of TNF-alpha inhibitor use to common benchmarks of risk

(2011) Edi Kaminska et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis

(2010) R.G. Langley et al.   BRITISH JOURNAL OF DERMATOLOGY

Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease

(2010) Mario Cottone et al.   Clinical Gastroenterology and Hepatology

Combination systemic therapies in psoriatic arthritis

(2010) Meaghan Daly et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study

(2010) Akihiko ASAHINA et al.   JOURNAL OF DERMATOLOGY

Tumor Necrosis Factor-α Inhibitor-Induced Psoriasis or Psoriasiform Exanthemata

(2009) Uwe Wollina et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Efficacy and Safety of Etanercept in Psoriasis after Switching from Other Treatments

(2009) Annamaria Mazzotta et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009

(2009) C.H. Smith et al.   BRITISH JOURNAL OF DERMATOLOGY

Increasing Burden of Melanoma in the United States

(2009) Eleni Linos et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

(2009) D Pathirana et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action

(2008) Angelique N. Collamer et al.   ARTHRITIS AND RHEUMATISM

Targeting tumor necrosis factor α in psoriasis and psoriatic arthritis

(2008) Francesca Fantuzzi et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Infliximab-induced hepatitis: absence of cross-toxicity with etanercept

(2008) Gérard Thiéfin et al.   JOINT BONE SPINE

Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximab

(2008) Keisuke Ojiro et al.   JOURNAL OF GASTROENTEROLOGY

Guidelines of care for the management of psoriasis and psoriatic arthritis

(2008) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Etanercept Treatment for Children and Adolescents with Plaque Psoriasis

(2008) Amy S. Paller et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor necrosis factor-α antagonists and neuropathy

(2007) Joerg-Patrick Stübgen   MUSCLE & NERVE

Patient-Reported Outcomes and Health-Care Resource Utilization in Patients with Psoriasis Treated with Etanercept: Continuous versus Interrupted Treatment

(2007) Joel M. Gelfand et al.   VALUE IN HEALTH